• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Flat; Initial Jobless Claims Fall To 210,000

    3/28/24 10:32:43 AM ET
    $AVTX
    $BDRX
    $GMDA
    $KOD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday.

    Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.

    Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 0.7% on Thursday.

    In trading on Thursday, information technology shares fell by 0.2%.

     

    Top Headline

     

    U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000.

     

    Equities Trading UP

     

    Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares shot up 435% to $24.91 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.

    Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) got a boost, surging 154% to $1.62 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.

    Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares were also up, gaining 92% to $1.65. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers.

     

    Equities Trading DOWN

     

    Primech Holdings Ltd. (NASDAQ:PMEC) shares dropped 49% to $1.98 after the company issued financial updates and corporate highlights for the six months ended Sept. 30, 2023.

    Shares of Gamida Cell Ltd. (NASDAQ:GMDA) were down 27% to $0.0434. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.

    Kodiak Sciences Inc. (NASDAQ:KOD) was down, falling 24% to $5.63 after the company reported a wider-than-expected fourth-quarter loss.

    Also Check This Out: Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer

     

    Commodities

     

    In commodity news, oil traded up 1.2% to $82.34 while gold traded up 0.6% at $2,226.90.

    Silver traded down 0.2% to $24.70 on Thursday, while copper fell 0.2% to $3.9905.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.2%, London’s FTSE 100 rose 0.4% while Spain’s IBEX 35 Index fell 0.1% The German DAX rose 0.1% French CAC 40 rose 0.1% while Italy’s FTSE MIB Index rose 0.1%.

    Bank lending to households in the Eurozone rose by 0.3% year-over-year to €6.87 trillion in February. The manufacturing confidence index in Italy climbed to 88.6 in March versus a revised reading of 87.5 in the prio month. German jobless rate came in steady at 5.9% in March, while German retail sales fell by 1.9% month-over-month for February.

    The British economy shrank by 0.2% year-over-year during the fourth quarter, while current account gap in the UK widened to £21.2 billion in the fourth quarter of 2023 versus a revised £18.5 billion gap in the prior period. UK car production climbed 14.6% year-over-year to 79,907 units in February.

     

    Asia Pacific Markets

     

    Asian markets closed mostly higher on Thursday, with Japan’s Nikkei 225 falling 1.46%, Hong Kong’s Hang Seng Index gaining 0.91%, China’s Shanghai Composite Index gaining 0.59% and India’s S&P BSE Sensex gaining 1.4%.

    Singapore bank loans rose to SGD 801.5 billion in February from SGD 794.3 billion in the prior month. The Domestic Supply Price Index in Singapore fell 2.8% year-over-year for February.

     

    Economics

     

    The U.S. economy grew an annualized 3.4% in the fourth quarter, up from 3.2% previously reported.

    U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000.

    The Chicago PMI declined to 41.4 in March from 44 in the previous month.

    U.S. pending home sales climbed by 1.6% from the prior month in February versus a revised 4.7% decline in the prior month.

    The University of Michigan consumer sentiment rose to 79.4 in March versus a preliminary reading of 76.5.

    Now Read This: $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

    Get the next $AVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $BDRX
    $GMDA
    $KOD

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Kodiak Sciences Inc
    $KOD
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    Kodiak Sciences Inc
    $KOD
    9/22/2025$15.00Buy
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    More analyst ratings

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Pricing of Underwritten Offering

    WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at a price to investors of $0.5349 per pre-funded warrant (the "pre-funded warrants"). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. The offering is

    2/11/26 9:34:13 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

    February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST). The compound also has the potential to be useful

    2/4/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

    PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothel

    2/4/26 7:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    SEC Filings

    View All

    SEC Form 424B5 filed by Xilio Therapeutics Inc.

    424B5 - Xilio Therapeutics, Inc. (0001840233) (Filer)

    2/11/26 5:16:58 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/10/26 4:07:24 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    2/4/26 8:51:45 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kodiak Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00

    11/11/25 8:00:12 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares, increasing direct ownership by 100% to 33,250 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    1/5/26 4:30:26 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $4,522 worth of shares (7,030 units at $0.64), increasing direct ownership by 99% to 24,766 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    1/5/26 4:30:21 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,174 worth of shares (1,826 units at $0.64), increasing direct ownership by 99% to 6,371 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    1/5/26 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Financials

    Live finance-specific insights

    View All

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

    Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

    2/12/25 7:35:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

    2/12/25 7:33:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $BDRX
    $GMDA
    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care